Inactive Instrument
Cyclacel Pharmaceuticals Inc Share Price Nasdaq
Stocks
US23254L1089
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 13/08 | Bio Green Med Solution, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2026 | CI |
| 05/06 | Bio Green Med Solution, Inc. and Future Nrg Sdn Bhd Announces Board Changes | CI |
| Market Cap | 58.28L 51.78L 48.33L 44.05L 83.08L 56Cr 83.85L 5.85Cr 2.27Cr 29Cr 2.19Cr 2.14Cr 92Cr | P/E 2024 |
-0.18x | P/E 2025 | -0.23x |
|---|---|---|---|---|---|
| Enterprise Value | 23.43L 20.82L 19.43L 17.71L 33.4L 23Cr 33.71L 2.35Cr 91.12L 12Cr 87.97L 86.06L 37Cr | EV / Sales 2024 |
-1,79,78,488x | EV / Sales 2025 | 50,43,119x |
| Free-Float |
64.75% | Yield 2024 * |
-
| Yield 2025 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Sing Ee Wong
CEO | Chief Executive Officer | 44 | 26/02/2025 |
Cu Seng Kiu
DFI | Director of Finance/CFO | 37 | 26/02/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Sing Ee Wong
BRD | Director/Board Member | 44 | 26/02/2025 |
Cu Seng Kiu
BRD | Director/Board Member | 37 | 26/02/2025 |
| Director/Board Member | 40 | 02/04/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +4.16% | +3.04% | +49.37% | +94.17% | 7.42TCr | ||
| -3.11% | -3.53% | +20.19% | +81.44% | 5.74TCr | ||
| +0.89% | -0.63% | +2.17% | +36.19% | 4.76TCr | ||
| +0.36% | +0.81% | +342.39% | +742.40% | 4.43TCr | ||
| -0.96% | -4.50% | +24.96% | +35.38% | 4.25TCr | ||
| -0.20% | -0.77% | +4.13% | +105.50% | 4.07TCr | ||
| -0.54% | +2.93% | +9.31% | +50.41% | 3.1TCr | ||
| -2.68% | +2.92% | +29.33% | +22.72% | 2.85TCr | ||
| +0.05% | -1.64% | -8.14% | -11.37% | 2.43TCr | ||
| Average | -0.23% | -0.59% | +52.63% | +128.54% | 4.34TCr | |
| Weighted average by Cap. | +0.12% | -0.84% | +56.96% | +138.26% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 0.04 0.04 0.04 0.03 0.06 4.13 0.06 0.43 0.17 2.11 0.16 0.16 6.78 | 0.75 0.66 0.62 0.56 1.06 71.81 1.07 7.5 2.9 36.71 2.8 2.74 117.82 |
| Net income | -1.12Cr -99.62L -92.98L -84.75L -1.6Cr -107.78Cr -1.61Cr -11Cr -4.36Cr -55Cr -4.21Cr -4.12Cr -176.84Cr | -29.98L -26.64L -24.86L -22.66L -42.74L -29Cr -43.14L -3.01Cr -1.17Cr -15Cr -1.13Cr -1.1Cr -47Cr |
| Net Debt | -31.37L -27.87L -26.01L -23.71L -44.72L -30Cr -45.14L -3.15Cr -1.22Cr -15Cr -1.18Cr -1.15Cr -49Cr | -34.85L -30.96L -28.9L -26.34L -49.68L -34Cr -50.14L -3.5Cr -1.36Cr -17Cr -1.31Cr -1.28Cr -55Cr |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
















